希望做 有专业深度的内容账号 ； 如果你喜欢和人打交道， 愿意走进真实的行业现场，采访专家、连接资源、推动事情落地； 如果你想参与一个账号、一场活动、一个内容项目从策划到执行的全过程—— 这个岗位，可能就是为你准备的。 如果你对 医疗科技、医学创新或前沿技术 感兴趣， 我们是谁？ 思宇 MedTech 是一家长期深耕医疗科技产业的专业内容与研究团队。 我们服务的是专业人群，包括但不限于： 我们正在持续打造医疗科技领域的 专业内容账号与行业活动体系 ，需要一位既能做内容、也能推动事情落地 的年轻运营型人才。 这个岗位是做什么的？ 这是一个偏"操盘型"的运营岗位， 活动 × 视频 × 内容项目的综合运营角色 你会参与： 1.行业活动与专家对接 2.短视频内容制作与出镜支持 拍摄行业活动现场、专家采访、花絮内容 医疗器械企业研发与管理层 临床医生与医学专家 一二级市场投资人 协助筹备医疗科技相关行业活动、论坛、闭门会 对接医生、企业嘉宾，协助安排采访与现场流程 现场支持活动执行、内容采集与嘉宾沟通 3.账号内容运营 4.内容项目协作 我们希望你是这样的应届生 专业背景 内容与视频基础 性格特质 喜欢与人沟通，不怕和 ...

Core Insights - The medical aesthetics industry is transitioning towards standardization and refinement, with a shift in competitive focus towards aesthetic expectations, treatment consistency, and operational efficiency [2] - The combination of energy devices, injection materials, and digital, intelligent tools is becoming a significant variable influencing the competitive landscape of the medical aesthetics industry [2] - The second Global Aesthetic Medical Technology Conference will be held on June 11-12, 2026, in Zhongguancun Conference Center, aiming to connect engineering technology, clinical practitioners, corporate innovation, capital, and regulation [2] Event Overview - The conference will feature three main components: the release of a white paper, award evaluations, and multi-theme forums, showcasing global medical aesthetics technology innovation and development trends [2][5] - A brand exhibition area will be set up at the venue to provide a concentrated display and connection space for innovative technologies, products, and solutions [2] White Paper Release - The conference will officially release the "2026 Global Aesthetic Medical Technology White Paper," focusing on the evolution of technology, product changes, corporate layouts, and industry structure in the medical aesthetics field [8] - The white paper serves as a significant window for companies to showcase their technological strength, product systems, and industry positioning [9] Award Evaluation - Multiple annual awards will be announced during the conference, covering various innovation dimensions in medical aesthetics technology, including energy devices, injection products, skin imaging, digital systems, and compliance trends [10][12] - The evaluation will adopt a third-party, neutral, research-oriented perspective, emphasizing long-term technological accumulation and standardized development [12] Multi-Theme Forums - The forums will address core topics with high attention and collaboration potential in the medical aesthetics field, such as energy device technology evolution, injection materials, digitalization trends, and regulatory compliance [13] - The forums aim to create a professional, rational, and multi-perspective dialogue system within the industry [14] Participation and Sponsorship - The conference is positioned as a platform for medical aesthetics technology companies to present their technological capabilities and product systems, connect clinical needs with industry resources, and build long-term content assets [16] - Various sponsorship forms will be available, targeting clinical practitioners, technology companies, industry observers, and investment representatives [16][23]

Core Viewpoint - The article emphasizes the unique position of the company, SiYu MedTech, as a professional team deeply engaged in the medical technology industry, focusing on producing in-depth content and industry research rather than traditional promotional activities [1]. Group 1: Company Overview - SiYu MedTech was established at the end of 2016 and has been operating for nearly nine years, with aspirations to recruit fresh graduates to join the rapidly evolving medical technology field by 2026 [2]. - The company serves professionals in the medical technology industry, producing specialized content that intersects clinical, technological, and industrial domains [3]. Group 2: Job Responsibilities - The role involves producing in-depth content related to various medical technology sectors, including surgical robotics, ophthalmology, cardiovascular, neurology, orthopedics, medical imaging, and aesthetic technology [3]. - Responsibilities include writing industry white papers, research reports, and systematic column planning, as well as providing content planning and communication support for medical device companies [3][4]. - The company focuses on translating technical language into industry-understandable terms and organizing industry conferences and closed-door discussions [4]. Group 3: Candidate Expectations - The company seeks candidates with a background in fields such as medicine, pharmacy, biomedical engineering, and related disciplines, with a preference for clinical or engineering backgrounds [8]. - Ideal candidates should be able to read and understand English literature, possess strong research skills, and be willing to engage with complex topics and iterative revisions [8]. Group 4: Work Environment and Benefits - The work environment allows for remote working, reducing commuting time and enabling focus on reading, thinking, and writing [13]. - The company offers flexible vacation arrangements, a stable work environment with no history of layoffs, and the opportunity for employees to engage in higher-difficulty projects as their skills grow [13].

Core Insights - The development logic of medical technology is shifting due to the upgrade of medical demand, engineering technology iteration, and the evolution of payment systems, with a focus on system-level solutions and industry collaboration [2] - The third Global MedTech Conference will be held on June 12, 2026, at the Zhongguancun Conference Center, aiming to connect engineering, clinical, corporate, capital, and regulatory aspects of medical technology innovation [2] - The conference will feature the release of a white paper, award evaluations, and multi-theme forums to present global medical technology innovation trends [2] Conference Overview - The conference will include a brand exhibition area for showcasing innovative technologies, products, and solutions, with reservations now open [3] - The second Global MedTech Conference highlighted the release of the "2026 Global Medical Technology Innovation White Paper" and awarded 11 innovation awards [4][6][7] - The white paper will provide a comprehensive framework for industry observation, focusing on technological evolution, product changes, corporate development models, and industry patterns [13][14] Key Themes - The white paper will cover high-end medical devices, surgical robots, medical imaging, digital healthcare, and the trends in registration and commercialization [15] - The conference will also feature awards for various categories, emphasizing long-term capabilities and systemic innovation [16][20] - Multi-theme forums will address topics such as medical technology innovation trends, engineering technology changes, and the commercialization path from R&D to market [17] Audience and Participation - The conference targets a diverse audience, including clinical experts, medical technology company leaders, industry observers, and investment representatives [21] - Sponsorship opportunities will provide structured, compliant, and sustainable collaboration paths for companies [22] - The event is positioned as an industry-focused, research-oriented conference rather than a purely academic or promotional meeting [23]

2026年2月4日，GE 医疗发布 2025 年第四季度及全年业绩。 在全球医疗设备行业整体仍受宏观波动、贸易环境变化与成本压力影响的背景下，GE 医疗交出了一份 收 入与每股收益均超出市场预期 的年报，并同步给出了指向明确的 2026 年增长与利润修复指引。 这份年报的价值在于其所呈现出的 增长结构、盈利弹性以及对外部冲击的吸收能力 。 # 全年表现：收入温和增长，但"质量"并不保守 从全年结果看，GE 医疗 2025 年实现营收 206亿美元 （约合人民币1430亿） ，同比增长 4.8% ，其中 有机收入增长 3.5% 。 在大型医疗设备公司中，这一增速并不激进，但其来源具有相当明确的结构性支撑。 驱动增长的核心业务包括： 三大板块共同贡献了全年收入的主要增量，而非依赖单一明星产品或短期项目集中释放。 更重要的是订单端的表现： 在医疗设备行业，这一组合意味着两点： 一是收入增长并非"透支式兑现"；二是公司在手订单（backlog） 为 2026 年提供了较好的可见度。 但利润端则出现阶段性回落： Imaging（影像） Pharmaceutical Diagnostics（药物诊断，PDx） Advan ...

近日， 国科离子医疗科技有限公司 宣布完成 首轮股权融资，募集资金约 8 亿元人民币 。 本轮融资由 社保 基金中关村自主创新专项基金（君联资本担任管理人） 与 君联资本 联合领投，资金将主要用于重离子及轻离 子治疗装备的持续研发、产业化推进及治疗中心布局。 这是近年来 国内粒子治疗装备领域金额较大的一笔市场化融资 ，也标志着国产重离子治疗系统正从技术验证 阶段，进一步走向规模化落地。 # 从科研装 置到临 床系统，重离子治疗实现国产突破 国科离子及其全资控股公司 兰州泰基离子技术有限公司 ，依托中国科学院近代物理研究所 三代人、50 余年 的重离子物理与医用加速器研究积累 ，已在肿瘤治疗装备产业化领域深耕 20 余年。 据公司公开信息，2019 年，公司成功研制出 我国首台拥有完全自主知识产权的碳离子治疗系统 ，并于 2020 年投入临床应用，打破了重离子放疗长期依赖进口的技术格局，使中国成为 全球第 4 个掌握重离子治 癌核心技术的国家 。 目前，该系统已在 甘肃武威等地实现稳定临床运行 ，并完成从科研装置向医疗器械体系的转化。 # 轻离子联合治疗装置落地，指向"降成本、提可及性" 据公开信息，重离子系统 ...

文章来源：神经未来 转载要求：可以直接转载，请在文首注明来源 2026年2月5日，证监会IPO辅导公示系统显示， 博睿康 已向上海证监局提交IPO辅导备案，正式启动上市进程 。 作为国内脑机接口（BCI）领域最早一批系统级企业之一，博睿康的核心产品为 微创植入式脑机接口系统 NEO 。据公开信息， NEO 已于 2025 年完成注册性临床试验，并进入国家药监局创新医疗器械特别审查程序， 有望成为 国内首个实现商业化落地 的植入式脑机接口产品 。 在海外脑机接口持续取得阶段性突破、国内政策与临床同步加速的背景下，博睿康的 IPO 动向，被视为中国医疗级 BCI 从"科 研主导"迈向"产业化验证"的重要信号。 # 海内外脑机接口进展提速，产业关注度持续升温 近一个月内，脑机接口赛道连续释放多重信号： 海外公司在侵入式技术路径上的持续突破，与国内企业在监管、临床和政策端的同步推进，使脑机接口从"前沿探索"逐步进入 可被资本 和产业评估的阶段 。 # 医疗仍是 BCI 最大基本盘，市场规模正在被重新评估 从全球视角看， 医疗健康是脑机接口当前最成熟、占比最高的应用方向 。 综合多家研究机构测算，医疗领域通常占整体 B ...

北芯生命 成立于 2015 年 12 月，总部位于深圳市，在深圳、香港、荷兰等地设子公司，北京、上海、 广州设有分公司，专注于心血管疾病精准诊疗创新医疗器械研发、生产和销售。 北芯生命是 国内首家拥有血管内功能学 FFR 及影像学 IVUS 产品组合 的国产医疗器械公司，改写了中国 冠状动脉疾病临床精准诊断完全依赖进口产品的局面 。 | | 血管内超声(IVUS)系 | TRUEVISION®血管内超声导管 &VivoHeart®血管内超声诊断仪 | | | | | --- | --- | --- | --- | --- | --- | | | 统 | | 1 | | | | | 血流储备分数 (FFR) | TRUEPHYSIO®压力微导管 | 1 | VivoCardio®血流储备分数测量设备 | | | | 系统 | | | | | | | 冠脉血管通路产品 | TrueCross 系列单腔微导管 | 1 | TrueReach®系列双腔微导管 | | | | | TrueExtensio®延长导管 | → | TrueReach®Ultimate双腔微导管 | 1 | | | | TrueExtens ...

Core Viewpoint - Boston Scientific's recent quarterly earnings report showed strong revenue and profit growth, but the stock price declined due to concerns over the slower-than-expected growth in the electrophysiology segment, which is critical for investor sentiment [1][5][6]. Overall Performance: Revenue and Profit Exceed Expectations - For Q4 2025, net sales reached $5.286 billion, a year-on-year increase of 15.9% (reported basis) and 12.7% organic growth [2][4]. - Net profit was $672 million, reflecting an 18.7% year-on-year growth, with adjusted earnings per share at $0.80, slightly above market expectations [2][3]. Stock Price Decline: Issues in Key Segment - Despite exceeding overall earnings expectations, Boston Scientific's stock price fell by over 10% in pre-market trading and nearly 15% during the day, primarily due to concerns in the electrophysiology (EP) segment [5]. - The EP segment's growth was approximately 35% year-on-year but fell short of market expectations by about 5 percentage points, leading to a revenue shortfall of approximately $33 million compared to consensus estimates [6][18]. Importance of Electrophysiology Segment - The electrophysiology segment, while not the largest, is one of the most scrutinized by capital markets due to its perceived strategic importance [6]. - The competitive landscape for pulsed field ablation (PFA) technology is intensifying, with Boston Scientific facing pressure on its market share as competitors enter the space [7][18]. Overall Business Growth - Excluding the electrophysiology segment, Boston Scientific's overall business remains robust, with significant growth across various segments [8][9]. - Key segment performances for Q4 included: - Cardiovascular: 18.2% growth - Urology: 13.8% growth - MedSurg: 11.7% growth - Neuromodulation: 11.1% growth - Endoscopy: 10.1% growth [12]. Mergers and Products: Strengthening Multi-Track Layout - In Q4 2025, Boston Scientific continued to pursue mergers and product advancements to diversify its portfolio, indicating a proactive approach to reduce reliance on any single product line [11][13]. - The company completed the acquisition of Nalu Medical and secured multiple agreements related to neurovascular technologies, enhancing its competitive positioning [13]. 2026 Guidance: Continued High Growth - Boston Scientific maintains a strong outlook for 2026, projecting double-digit revenue growth despite already exceeding $20 billion in size, which is uncommon among global medical device giants [15]. Conclusion: Market Reassessing Growth Structure - The key takeaway from the earnings report is not a slowdown in growth but rather a market reassessment of growth structures, emphasizing the importance of multi-segment collaboration over reliance on a single standout product [16][18].

Core Insights - Nina Goodheart, the Senior Vice President and President of Medtronic's Structural Heart and Aortic business, announced her retirement after nearly 20 years with the company, marking the end of a significant career [1][3] Group 1: Leadership Background - Nina Goodheart joined Medtronic in 2007, initially focusing on the Cardiac Rhythm and Heart Failure (CRDM) market, and later held various key management positions [3] - Over the past five years, she led the Structural Heart and Aortic business, witnessing its evolution from a single product competition to a platform-based approach with expanded indications and long-term follow-up [3][5] Group 2: Business Progress During Tenure - Under her leadership, the core focus of Medtronic's Structural Heart business was clear, emphasizing the following: 1. Continuous advancement of the transcatheter aortic valve platform 2. Differentiated layout for transcatheter pulmonary valves 3. Promotion of clinical research and conceptual development [6] - The Evolut series of transcatheter aortic valve systems has seen ongoing iterations, maintaining a leading position in the global TAVR competition, while the Harmony transcatheter pulmonary valve system targets a niche market with high technical barriers [7] Group 3: Conclusion and Industry Implications - Goodheart's retirement is viewed as a normal conclusion of an executive career cycle rather than a sign of business pressure or strategic shifts [9] - The news holds value for industry stakeholders interested in how global leaders in the mature structural heart business achieve long-term stable operations [9]